Mark Leuchtenberger, who tried, and failed, to develop an antibiotic at Targanta, is getting another crack at the same target. Leuchtenberger has been hired to take over as CEO of Rib-X in New Haven, CT. Founder Susan Froshauer will retain her title as CSO. Leuchtenberger sold Targanta to The Medicines Company in early 2009 after the FDA rejected the company's application for its lead antibiotic, oritavancin, and forced the developer to lay off 75 percent of its staff. Release | Report